BUZY PETER L 4

4 · Catalent, Inc. · Filed May 21, 2019

Form 4

Period: 2019-05-17

President, Gene Therapy

Transactions

Award
Options to purchase Common Stock
2019-05-17+230,093→ 230,093 total
Exercise: $0.88From: 2019-05-17Exp: 2024-12-16→ Common Stock (230,093 underlying)
Award
Restricted Stock Units
2019-05-17+44,082→ 44,082 total
Exercise: $0.00From: 2021-05-17Exp: 2021-05-17→ Common Stock (44,082 underlying)
Award
Options to purchase Common Stock
2019-05-17+161,813→ 161,813 total
Exercise: $45.37From: 2021-05-17Exp: 2029-05-17→ Common Stock (161,813 underlying)

Footnotes (5)

[F1]Options to purchase common stock received by the reporting person under the Issuer's omnibus incentive plan in connection with the assumption of certain vested, in-the-money options held by reporting person under the incentive plan of Paragon Bioservices, Inc. coincident with that entity's acquisition by one of Issuer's subsidiaries. The number of options and the exercise price thereof are subject to adjustment based on post-closing net purchase price adjustments.
[F2]Options to purchase common stock received by the reporting person under the Issuer's omnibus incentive plan in connection with reporting person's election as an executive officer of Issuer.
[F3]Vesting as to 50% of the options may be accelerated based on the satisfaction of certain performance criteria.
[F4]Restricted stock units (RSUs) received by the reporting person under the Issuer's omnibus incentive plan in connection with reporting person's election as an executive officer of Issuer. Each RSU represents the right to receive one share of the Issuer's common stock as of the date of vesting.
[F5]Vesting will not occur, and the RSUs will be forfeited, if reporting person fails to purchase and hold an agreed-upon amount of the Issuer's common stock through the scheduled vesting date.

Documents

1 file